July 16, 2017
Washington D.C. – UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder and CEO, Bernard A. Fox, PhD, will speak on July 20 at a workshop in the Capitol organized by the US Food & Drug Administration (FDA) and the American Association for Cancer Research (AACR). On July 19 Dr. Fox will speak at a US congressional briefing organized by AACR and the Society for Immunotherapy of Cancer (SITC), entitled Progress in Immuno-Oncology: Delivering Hope and Clinical Benefit to Cancer Patients.
According to Dr. Fox the FDA-AACR meeting has special significance for wider use of combination cancer immuno-therapies and will focus on approaches to combination therapy and best practices regarding patient and dose selection, biomarkers to aid in selection, and novel endpoints that can define patient benefit.
“The FDA is being proactive and working with academic and industry partners to discuss the role of biomarkers in patient selection and, in the case of combination studies to identify how to demonstrate the contribution that each agent has to a combination immunotherapy. In UbiVac’s case, where we will combine DPV-001 with co-stimulatory and checkpoint agents, this relates to our data obtained from patients receiving adjuvant treatment with DPV-001 alone.”
Dr. Fox, is a past president of SITC, chair of the World Immunotherapy Council and an internationally recognized expert in cancer immunotherapy.
Contact: Patricia Pearson, firstname.lastname@example.org
Award Number R44CA121612 from the National Cancer Institute supports the research and clinical trial of DPV-001 in patients with NSCLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 recently completed a Phase II randomized multi-center adjuvant study for non-small cell lung cancer that documented efficacy for induction or boosting of broad anti-cancer immunity. Based on these data UbiVac is planning to open a phase Ib/II study of DPV-001 + anti-OX40 in patients with advanced cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.